R&D Expenses: Strategic Insights for Foreign and U.S. Companies Under the “One Big Beautiful Bill”.

Research and Development (R&D) expenses represent a critical investment for both U.S. and foreign companies seeking to innovate, enhance competitiveness, and expand market presence. With significant legislative shifts anticipated—most notably under the proposed “One Big Beautiful Bill”—the approach to claiming and deducting R&D expenses is evolving. These changes present both new opportunities and compliance challenges for global businesses.

Before the introduction of the “One Big Beautiful Bill,” U.S. companies could typically deduct qualified R&D expenditures immediately. However, under recent rules, businesses were required to capitalize and amortize these expenses over five years for domestic R&D and 15 years for foreign R&D. This created deferred tax benefits and heightened administrative burden, requiring firms to implement robust tracking systems and adjust their financial reporting to reflect multi-year deductions.

Companies must also balance decisions between amortization and pursuing R&D tax credits. For domestic R&D, taxpayers can generally elect to amortize expenses or claim the R&D credit (under Section 41) if the activity meets IRS criteria. In contrast, foreign-incurred R&D costs are limited to amortization over 15 years, as credits typically do not apply. Strategic allocation and documentation of research activities are thus essential to optimizing the overall tax position.

Understanding R&D Expenses

R&D expenses encompass costs associated with developing new products, improving technologies, and conducting innovative activities. Under Section 174 of the Internal Revenue Code, qualified expenditures may be deductible or amortized, depending on the current legislative framework. Policy distinctions can significantly affect both U.S. and foreign companies, depending on the nature and location of their R&D investments.

Foreign Companies: Navigating U.S. R&D Tax Opportunities

Foreign entities with U.S. operations face nuanced compliance considerations. To benefit from R&D credits or deductions, foreign firms must substantiate that qualifying R&D activities occur within the United States. This typically requires:

• Employing U.S.-based personnel
• Conducting research domestically
• Maintaining contemporaneous records supporting the purpose and substance of each expense

A well-structured U.S. presence enables foreign firms to capture available incentives while mitigating exposure to IRS scrutiny.

U.S. Companies: Seizing New Deduction Potential

For U.S. companies, the R&D deduction has long supported innovation-led growth. The current requirement to amortize R&D expenditures over five years has limited immediate liquidity benefits. The “One Big Beautiful Bill,” however, proposes reinstating immediate expensing under Section 174. If enacted, this shift will allow companies to regain rapid tax relief, improving cash flow and expanding reinvestment capacity. Businesses should proactively evaluate tax planning under both current and proposed frameworks.

The “One Big Beautiful Bill”: Implications for R&D Deductions

The proposed bill aims to simplify tax compliance and stimulate innovation by restoring immediate R&D expensing. This change will reduce the administrative complexity tied to amortization schedules while providing near-term financial benefit to both U.S. and qualifying foreign-controlled corporations. Businesses should track legislative progress closely and be ready to adapt accounting methodologies once enacted.

Action Steps for Tax Efficiency

1. Stay Informed: Monitor legislative updates and IRS guidance related to Section 174 and R&D credits.
2. Enhance Documentation: Keep detailed records of R&D activities, costs, and related business purposes.
3. Assess U.S. Footprint: Foreign entities should ensure sufficient domestic activity to qualify for deductions or credits.
4. Plan for Transition: Prepare systems and ledgers for immediate expensing if enacted under the new bill.
5. Engage Advisors: Work with tax professionals to model financial impacts and optimize credit utilization.

 Reporting R&D Expenses and Credits

Guidance for Tax Professionals and Corporate Filers Through 2025 and Beyond

IRS Form 1120 R&D Reporting (2025)

For the 2025 tax year, corporations must report R&D expenses on Form 1120, typically under “Other Deductions” (line 26) and Schedule M-1. Amortized Section 174 expenditures must be supported by detailed statements specifying cost types and amortization computations.

R&D tax credits are claimed via Form 6765 (“Credit for Increasing Research Activities”) and reflected on Form 1120, line 6a. Proper documentation is essential to support both claimed expenses and credit computations.

IRS Form 1120 R&D Reporting (2026 and Beyond)

If the “One Big Beautiful Bill” is enacted, immediate expensing under Section 174 would resume starting tax year 2026. Reporting would simplify, as companies could deduct the full cost in the year incurred. Updated IRS instructions will define revised disclosure and schedule requirements.

Form 6765 Key Elections

Form 6765 enables several tax elections critical for strategic R&D planning:

• Payroll Tax Credit (ESB Election): Eligible small businesses (under $5 million in current-year receipts, none before the five-year lookback) may apply a portion of the R&D credit against employer payroll tax.
• Section 280C(c)(3) Election: Allows claiming a reduced credit to avoid deduction disallowance.
• Credit Computation Method: Taxpayers may choose between the regular and Alternative Simplified Credit (ASC) methods.

Each election must be properly disclosed and supported with documentation to withstand IRS review.

Transition Planning: Adjustments After Enactment

Companies that have capitalized R&D costs under current law will need to reassess unamortized balances once immediate expensing becomes available. This may involve reclassifying remaining capitalized costs as deductible expenses during the transition year, supported by detailed schedules showing reversal entries and timing adjustments. Transparent documentation will be vital for audit readiness and accurate tax reporting.

Conclusion

Precision in reporting and strategic election management on IRS Forms 1120 and 6765 is fundamental to optimizing R&D tax benefits. As the potential for immediate expensing under the “One Big Beautiful Bill” draws near, companies should align their documentation, compliance procedures, and planning to capitalize on restored flexibility. Proactive action today will ensure businesses maximize the benefits of evolving tax policy while maintaining compliance and audit defense readiness.